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The blaESBL and blaAmpC genes in Enterobacteriaceae are spread by plasmid-mediated integrons, insertion
sequences, and transposons, some of which are homologous in bacteria from food animals, foods, and
humans. These genes have been frequently identiﬁed in Escherichia coli and Salmonella from food animals,
the most common being blaCTX-M-1, blaCTX-M-14, and blaCMY-2. Identiﬁcation of risk factors for their occur-
rence in food animals is complex. In addition to generic antimicrobial use, cephalosporin usage is an impor-
tant risk factor for selection and spread of these genes. Extensive international trade of animals is a further
risk factor. There are no data on the effectiveness of individual control options in reducing public health
risks. A highly effective option would be to stop or restrict cephalosporin usage in food animals. Decreasing
total antimicrobial use is also of high priority. Implementation of measures to limit strain dissemination (in-
creasing farm biosecurity, controls in animal trade, and other general postharvest controls) are also important.
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In the last decade a variety of plasmid-mediated ß-
lactamases have emerged in gram-negative bacteria.
These included both extended-spectrum ß-lactamases
(ESBLs) and AmpC ß-lactamases (AmpC).
ESBLs confer resistance to a variety of ß-lactams, in-
cluding penicillins, ﬁrst-, second-, third-, and fourth-
generation cephalosporins, and monobactams, but
usually not to the carbapenems or the cephamycins
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(Table 1). The most frequent ESBLs in Enterobacteriaceae
belong to the TEM, SHV, and CTX-M families. There are also
some class D ß-lactamases (so-called oxacillinases) that might
be considered “extended spectrum” enzymes.
Before 2000, SHV and TEM types of ESBLs were the predom-
inant variants found in Klebsiella species and Escherichia coli,
mainly causing human nosocomial infections. The correspond-
ing genes were often located on transmissible plasmids, facilitat-
ing their efﬁcient spread. During the last decade, CTX-M–type
enzymes spread worldwide, being now the most prevalent
ESBLs in human Enterobacteriaceae. Whereas ESBLs used to be
produced mainly by nosocomial Klebsiella pneumoniae, community-
acquired E. coli producing CTX-M enzymes (speciﬁcally CTX-
M-15) has been increasingly reported.
AmpC β-lactamases are intrinsic cephalosporinases found
on the chromosome of many gram-negative bacteria. These
enzymes confer resistance to penicillins and to ﬁrst-, second-,
and third-generation cephalosporins, including β-lactam/
inhibitor combinations and cephamycins, but usually not to
fourth-generation cephalosporins and carbapenems. A growing
number of AmpC enzymes have now “escaped” onto plasmids
(termed “acquired” or “plasmidic” AmpCs). Such enzymes fall
into 6 phylogenetic groups, with CMY-2 being the most
common.
Signiﬁcance and Public Health Threat of Human Infections With
ESBL/AmpC β Lactamase–Producing Bacteria
Community- and healthcare-associated infections with ESBL/
AmpC β-lactamase–producing bacteria have been increasingly
reported worldwide [1]. Reports from the European Antibiotic
Resistance Surveillance System show that in hospitals in
Europe, rates of invasive E. coli and K. pneumoniae isolates
resistant to cefotaxime and ceftazidime have been increasing
since 2000 [2]. This is recognized as a public health threat
because resistance to β-lactams and coresistance to other anti-
microbial classes (eg, the ﬂuoroquinolones) limit the choice of
effective antimicrobial agents available for treatment and com-
monly used as ﬁrst-line therapy [1]. Moreover, infections with
ESBL/AmpC β-lactamase–producing bacteria may result in
delays in the initiation of timely and adequate antimicrobial
therapy [3], increased morbidity and mortality, longer hospital
stays, and higher costs [3, 4].
Of the many risk factors found associated with patient colo-
nization or infection with ESBL or AmpC ß-lactamase–
producing bacteria [5, 6], prior antibiotic use, especially with
the oxyimino-ß-lactams (cefuroxime, cefotaxime, ceftriaxone,
ceftazidime, or aztreonam) [7, 8], ﬂuoroquinolones [9] and
ß-lactam–ß-lactamase inhibitor combinations [9], has been
consistently reported.
Possible Reservoirs of ESBL/AmpC β-Lactamase–Producing
Bacteria
Transmission of ESBL-producing Enterobacteriaceae from
person to person has been demonstrated in hospital, communi-
ty, and household settings, the evidence strongly suggesting that
human intestinal colonization with these resistant organisms
serves as a reservoir for spread [10–12]. The primary reservoirs,
however, of such organisms are still contentious. ESBL/AmpC-
producing E. coli and Salmonella have been isolated from food
animals in many European countries, particularly poultry and
cattle, and farm animals are now recognized as important carri-
ers [13]. Similarly, there have been an increasing number of
Table 1. Main Hydrolytic Characteristics of Extended-Spectrum β-Lactamases and AmpC
Antimicrobial Classes Examples of Antimicrobials ESBL Hydrolytic Activity AmpC Hydrolytic Activity
Penicillins Penicillin G, amoxicillin, ampicillin,
ticarcillin, piperacillin
+++ +++ (exception is ticarcillin: no
hydrolysis)




AmpC activity is not neutralized
by the inhibitor
First-gen cephalosporins Cefazolin, cefalexin, cefalotin +++ +++
Second-gen cephalosporins Cefaclor, cefuroxime ++ ++
Third-gen cephalosporins Cefotaxime, ceftazidime, ceftriaxone ++ + (if produced at a basal level)
+++ (if overproduced)
Fourth-gen cephalosporins Cefepime ++ +/–
Monobactams Aztreonam ++ ++
Cephamycins Cefoxitin, cefotetan – +++
Carbapenems Imipenem, meropenem, ertapenem,
doripenem
– – or +/− (depending on the type
of ß-lactamase)
Abbreviations: +++, high level of hydrolysis; ++, medium level of hydrolysis; +, weak level of hydrolysis; +/−, none or very weak hydrolysis which can contribute
to and influence the final susceptibility results, usually only if combined with additional resistance mechanisms; –, no hydrolysis; ESBL, extended-spectrum
β-lactamase; gen, generation.
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reports of isolations from foods of animal origin [14]. These
reports raise questions about the possible role of animal- and
food-related reservoirs in the spread of ESBL/AmpC-producing
microorganisms. This paper reviews the public health risks of
bacterial strains producing ESBL or AmpC enzymes in food and
food-producing animals, with particular reference to the situa-
tion in the European Union (EU). Methods for their detection
and possible control options to limit their spread are discussed.
ESBL- AND AmpC-PRODUCING BACTERIAL
STRAINS AND GENES RELEVANT FOR PUBLIC
HEALTH AND LINKED TO FOOD-PRODUCING
ANIMALS OR FOODBORNE TRANSMISSION
Occurrence and Epidemiology of Acquired Resistance to Broad-
Spectrum Cephalosporins in Food-Producing Animals and Food
Ofﬁcial harmonized monitoring of resistance to third-generation
cephalosporins in EU member states is based on cefotaxime
susceptibility patterns. In those EU countries reporting such
resistance, the occurrence of cefotaxime resistance was low
among E. coli and Salmonella isolates recovered from nonse-
lective plates. Total prevalences in different animal species and
meat in 2009 ranged from 0.4% to 5% for Salmonella, and
from 2% to 9% for E. coli [15].
In studies targeted to detect ESBL or AmpC genes, the per-
centages of samples of food-producing animals or food in
which ESBL-carrying E. coli were detected varied from 0.2% to
40%. Percentages of occurrence ranged from 10% to 40% in
Portugal, the Netherlands, and France, with slightly lower per-
centages in other countries [15]. In a pilot study carried out in
the Netherlands, 100% of broiler farms and >80% of animals
were positive for ESBL E. coli [16]. The prevalence of ESBLs
among Salmonella isolates was much lower than for E. coli, with
percentages of <1% found in 2 studies in Germany and Spain,
respectively [17, 18]. The methodology used in the different
studies is heterogeneous, and comparisons are therefore difﬁcult.
ESBL-producing (eg, TEM, SHV, CTX-M, PER) and AmpC-
producing (eg, CMY, DHA-1, ACT-1) organisms have been de-
tected in food-producing animals (poultry, swine, bovines,
horses, rabbits, ostriches, wild boar), marine aquaculture
systems, and foods of animal origin [15]. The most common
ESBL genes are those encoding CTX-M enzymes. In food-
producing animals and food in EU countries, 11 different ESBL
subtypes of the CTX-M type have been described, with CTX-
M-1 being most common [15]. Although CTX-M-15 has spread
in a pandemic fashion in humans, the enzyme type has been
only recently been reported in food-producing animals or food,
and then only in very few EU countries [19–21]. SHV ESBLs, in
particular SHV-12 and SHV-2, have been also frequently detect-
ed throughout the European Union. The most frequently detect-
ed TEM ESBL has been TEM-52, whereas TEM-20 has been
less common. The type of AmpC β-lactamase detected was
almost always the CMY-2 variant [15]. ESBL producers have
been mostly found in Europe, whereas AmpC producers have
been particularly common in North America, mirroring the
trends for human isolates. ESBL and AmpC genes have most
frequently been detected in E. coli and nontyphoidal Salmonella
in isolates from terrestrial food-producing animals; and in Aero-
monas, Vibrio, and Edwardsiella species from ﬁsh [15].
Transmission of ESBL/AmpC genes in both humans and ani-
mals is mainly driven by the IncF, IncI, IncN, IncA/C, IncL/M, and
IncK plasmid families [22]. Most of these plasmid types can only
replicate within Enterobacteriaceae, and show a narrow host range
(ie, IncF, IncI, IncK). Plasmids of other families (ie, IncA/C) can
replicate within the species of many genera and even families, and
are deﬁned as broad-host-range plasmids. IncA/C plasmids have
been associated with the spread of blaCMY-2 in both the United
States and the United Kingdom [23] and IncN, IncI, and IncL/M
plasmids with the spread of blaCTX-M-1, blaCTX-M-3, and blaTEM-52
in Europe [24]. IncK plasmids carrying the blaCTX-M-14 gene have
become diffused in both Spain and the United Kingdom [25].
Clonal expansion of ESBL/AmpC producers has also been
documented. Speciﬁc clones of E. coli such as B2–E. coli O25b:
H4-sequence type (ST) 131, D–E. coli O25a-ST648, and D–
E. coli ST69 and ST393 have been increasingly detected among
humans and animals [20, 26–28]. Other clones of E. coli (ST57,
ST156, ST371) are widespread among poultry in some EU
countries and in Japan [29–31]. Recent reports documenting
outbreaks of ESBL producers of Shiga toxin–producing E. coli
clones O111:H8 and O104:H4 linked to food or food-producing
animals are of concern [32, 33]. A range of Salmonella serovars
(Salmonella Agona, Salmonella Virchow, Salmonella Infantis,
Salmonella Typhimurium) have been associated with the dis-
semination of ESBLs in poultry, cattle, and pigs. AmpC produc-
ers of Salmonella Heidelberg and Salmonella Newport have
been reported, mostly in cattle in North America [15]. The di-
versity of genetic contexts and clonal or plasmid backgrounds is
comprehensively tabulated elsewhere [15].
Transmission of ESBL/AmpC-Resistant Bacterial Strains or
Resistance Genes to Humans by Consumption or Handling of
Contaminated Food or Through the Food-Animal Production
Environment
There are few studies that provide evidence of the existence of
common clones of ESBL- or AmpC-producing E. coli in foods
of animal origin and in humans [19, 21, 34]. Transmission of
ESBL/AmpC-producing Salmonella from different animal
species, including poultry, to humans throughout the food
chain has been suggested in different studies [15], although
the evidence with regard to the possibility of spread of such
organisms to humans via direct contact with animals, or indi-
rectly via the environment, is limited [35]. People working
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with poultry have been demonstrated to have a higher risk for
intestinal carriage of ESBL/AmpC-producing bacteria [36].
The occurrence of Enterobacteriaceae resistant to carbapenems
is a growing threat in humanmedicine. The presence of such resis-
tance in bacteria from animals is largely unknown, although E. coli
producing VIM-1 carbapenemase resistance has been recently re-
corded in pigs in Germany [37]. As yet, there are no indications
of the zoonotic transfer of such resistance to humans.
METHODS (PHENOTYPIC AND GENOTYPIC),
AND THE INTERPRETIVE CRITERIA
CURRENTLY USED FOR DETECTION
(ISOLATION AND IDENTIFICATION) AND
CHARACTERIZATION OF ESBL- OR AmpC-
PRODUCING BACTERIAL STRAINS, ESBL- OR
AmpC-ENCODING GENES, AND ASSOCIATED
MOBILE ELEMENTS
Isolation from animal feces or foods is optimally performed
with selective growth media preceded by selective enrichment
in broth, using low concentrations of cefotaxime or ceftriax-
one as the selective agent. Suspected isolates are identiﬁed and
conﬁrmed as ESBL or AmpC producers by phenotypic conﬁr-
mation tests using harmonized interpretive criteria such as
those proposed by the European Committee on Antimicrobial
Testing of the Clinical and Laboratory Standards Institute).
Final identiﬁcation is performed by molecular characterization
of the genes conferring resistance.
Molecular identiﬁcation of ESBL or AmpC genes is per-
formed by screening assays using polymerase chain reaction
(PCR) or microarray, and subsequent sequence analysis. Lists
of primers for the most important β-lactamases in Enterobac-
teriaceae have been published [38]. Several commercial micro-
arrays have been developed for rapid and speciﬁc detection of
β-lactamase genes [39, 40]. Identiﬁcation of the subtype of the
ESBL or AmpC genes detected by PCR or microarray is nor-
mally conducted by sequence analysis of PCR fragments.
Plasmid isolation and electrophoresis in agarose gels pro-
vides information on the number and mass/size of plasmids
present in one isolate. Transfer of plasmids to well-character-
ized recipients by conjugation or electroporation facilitates the
typing of individual plasmids. Categorization of plasmids in
incompatibility groups can be performed by PCR-based repli-
con typing method, targeting the major plasmid families of
Enterobacteriaceae [41]. Novel plasmid families can be recog-
nized by complete DNA sequencing, also using the relaxase
gene as a phylogenetic marker [42]. Further characterization
of plasmids belonging to groups I, F, N, HI2, and HI can be
performed by plasmid multilocus sequence typing (MLST)
[43] (http://pubmlst.org/plasmid/).
The purpose of molecular typing is to determine genetic re-
latedness of isolates to allow source tracking/attribution. The
discriminatory power varies among methods, and inﬂuences
the conclusions that can be drawn from the results. The
choice of method is determined by the goal of the work.
Pulsed-ﬁeld gel electrophoresis or multiple loci variable
number of tandem repeats analysis are often used to identify
clonal clusters of isolates that are related to a certain “out-
break” in a restricted time frame. MLST is often the method
used to identify the relatedness of isolates of the same species
from different backgrounds (eg, animal vs human).
RISK FACTORS CONTRIBUTING TO THE
OCCURRENCE, EMERGENCE, AND SPREAD OF
ESBL- OR AmpC-PRODUCING BACTERIAL
STRAINS IN FOOD-PRODUCING ANIMALS AND
FOOD
A variety of farm management factors may facilitate the intro-
duction and spread of ESBL- and AmpC-producing bacteria
(eg, animal exposure to contaminated water or feed; absence
of water acidiﬁcation in poultry production) [44, 45]. The
establishment of risk factors for occurrence of ESBL/AmpC-
producing bacteria is complicated by scarcity or lack of accu-
racy of reliable data. Further research is needed to understand
more about the driving forces that have led to the rapid spread
of these resistant bacteria in many countries worldwide.
Most ESBL- and AmpC-producing strains may carry addi-
tional resistances such as to sulfonamides and other commonly
used veterinary drugs. Therefore, persistence and dissemination
of ESBL/AmpC-producing bacteria can be selected for by the
use in food-producing animals, not only of cephalosporins, but
also of other compounds such as amoxicillin, sulphonamides,
trimethoprim, ﬂuoroquinolones, and aminoglycosides [44, 45].
The most efﬁcient selection pressure will be driven by systemic
use of third- and fourth-generation cephalosporins. A strong
correlation between a reduction in ceftiofur-resistant Salmonella
Heidelberg and ceftiofur-resistant E. coli (both producing
AmpC) from both human infections and retail poultry in dif-
ferent regions of Canada and withdrawal of ceftiofur for disease
prophylaxis in hatcheries has been reported [46]. In the Europe-
an Union, approved systemic use of third- and fourth-generation
cephalosporins is limited to cases that are expected to respond
poorly to other antimicrobials; no use is approved for poultry.
Off-label use of cephalosporins also occurs. For instance, cef-
tiofur has been used prophylactically in 1-day-old piglets [47],
and there are also indications of its widespread off-label use of
in poultry (eg, in ovo use, or use as spray or by subcutaneous
injection in hatcheries). Moreover, illegal use has likely in-
creased owing to simpliﬁed access through the Internet.
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An extensive trade of animals occurs in the European Union,
with few countries leading the production and the export, and
with a small number of companies producing pure-line grand-
parent stock. How widespread are ESBL-carrying bacteria in
food-producing animals is generally unknown, although few
reports suggest that ESBL/AmpC are not uncommon in the top
of some production pyramids. In Sweden, transmission of resis-
tant bacteria from imported breeding chickens was documented
by ﬁndings of E. coli carrying genes in environmental samples
from hatcheries rearing production animals or breeding stock
(parent animals) [48]. Recent data from the Netherlands indi-
cate that ESBL- or AmpC-producing E. coli are introduced in
the Dutch poultry production chain through imported day-old
grandparent chickens. Moreover, the data indicate that the oc-
currence of these organisms in the different levels layers of the
Dutch poultry production chain is the result of vertical trans-
mission, local recirculation, and selection [36, 49].
Contamination of meat products with resistant bacteria
may contribute to further spread within the human popula-
tion. This has been shown to be particularly applicable to
ESBLs, where genes might rapidly transfer from foodborne
commensals to human pathogens [34, 50].
Contamination of food of plant origin with bacteria producing
ESBLs or AmpC has also been recognized, as demonstrated by
the recent large outbreak caused by CTX-M-15–producing
E. coli O104:H4 linked to the consumption of contaminated
sprouts [51].
Recommendations for further research are (1) to undertake
risk assessments to quantify relationships (if any) between the
occurrence of ESBL/AmpC-producing bacteria in food-
producing animals and antimicrobial consumption (both of
cephalosporins and all antimicrobials overall) and (2) to
perform cross-sectoral studies to assess and quantify factors
contributing to the emergence and dissemination of ESBL/
AmpC resistance in different food animal species.
POSSIBLE CONTROL OPTIONS TO REDUCE THE
PUBLIC HEALTH RISK CAUSED BY ESBL- OR
AmpC-PRODUCING BACTERIAL STRAINS
TRANSMITTED VIA THE FOOD CHAIN OR THE
FOOD-ANIMAL PRODUCTION ENVIRONMENT
The effect of reducing the prevalence of ESBL- or AmpC-
producing bacteria in animals or food on public health risks is
difﬁcult to assess. Although there is evidence of the contribution
of resistant microorganisms transmitted via food-producing
animals and food to public health risks, it is difﬁcult to quantify
that risk. Moreover, the magnitude of the contribution from
Table 2. Main Measures to Control the Selection and Dissemination of Extended-Spectrum β-Lactamase/AmpC-Producing Organisms
in Food-Producing Animals (Based on Best Available Evidence and Expert Opinion)
Control Measure Options
Stop/reduce the use of
cephalosporins in food animals
• Provided adequate compliance, the measure would be more effective the more comprehensive the
restrictions.
• The restrictions could range from stopping all uses of cephalosporins/systemically active third- and
fourth-generation cephalosporins, to more or less strict restriction of their use, allowing use only
under specific circumstances.
Increase compliance with existing
legislation
• Off-label use of veterinary medicinal products, including cephalosporins, is restricted according to
articles 10 and 11 of Directive 2001/82/EC as amended. Such use should be limited to use by way
of exception, under the veterinarian’s direct personal responsibility and in particular to avoid causing
unacceptable suffering.
Decrease the total antimicrobial
use in animal production in the
European Union
• To implement systems to monitor and control antimicrobial usage at MS and EU level
• To implement measures to ensure transparency in antimicrobial usage (at farm and prescriber level)
• To promote more tailored treatments by implementation of adequate diagnostic tools
• To launch information campaigns on prudent use principles targeting farmers and responsible
veterinarians
• To stop antimicrobial use at hatcheries
Implement measures to control
dissemination
• To promote closed production systems with high biosecurity standards
• To introduce EU monitoring systems to control trade of ESBL/AmpC-contaminated food-producing
animals in production pyramids
• To improve hygiene throughout the food chain
Control antibiotic use and
dissemination in the poultry
production pyramid
• To restrict antimicrobial use in poultry production
• To implement infection control measures to prevent vertical transmission from the top of the
poultry production pyramid
• To improve hygienic measures to prevent local recirculation within subsequent flocks
Abbreviations: ESBL, extended-spectrum β-lactamase; EU, European Union; MS, member state.
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animals and foods to public health risks, and the perception of
the risks for humans, will be greatly inﬂuenced by the local epi-
demiology of ESBL- or AmpC-producing organisms in health-
care settings and in the community. This epidemiology may
vary greatly by country. In countries where human associated
ESBL- or AmpC-producing clones have spread endemically in
healthcare settings and the community, contaminated animals
and foods will have a minor relative importance compared to
countries where these organisms occur only incidentally in
healthcare settings and the community.
Public health risks caused by ESBL- or AmpC-producing
bacteria are primarily determined by (1) the frequency of the oc-
currence (prevalence) and the quantity of these organisms in
food-producing animals and food, (2) the genetic characteristics
of the β-lactamase genes involved, and (3) the transmission from
animals or food to humans. Mitigation measures should therefore
aim to reduce the prevalence in animals and food, and to reduce
transmission from contaminated animals and foods to humans.
The prevalence of resistant organisms in a certain niche
(animals or foods) is determined by 2 basic mechanisms: (1)
selection by antibiotic usage and (2) dissemination within
farms and animal production chains.
There are no data on the comparative efﬁciency of individual
control options in reducing public health risks caused by ESBL-
or AmpC-producing bacteria related to food-producing animals.
Prioritization is complex, and the effectiveness of measures dis-
cussed is based on the best available evidence and expert opinion
(Table 2). As such, a highly effective control option to reduce
selection of ESBL/AmpC-producing bacteria at an EU level
would be to stop all uses of cephalosporins or systemically active
third- and fourth-generation cephalosporins, or to restrict their
use (ie, only allowed under speciﬁc circumstances). The more
comprehensive the restriction, the more prominent would be the
effect on selection pressure, although a very restrictive policy
might have unintended consequences on animal health and
welfare if effective antimicrobials are not available for treatment.
Efforts should be directed to the implementation of measures
intended to minimize off-label use of cephalosporins. Because
coresistance is an important issue, decreasing the total antimi-
crobial use in animal production in the European Union is also
of high priority. Also of importance (more so after the ESBL/
AmpC-producing microorganisms have emerged) are the mea-
sures to control their dissemination, such as by implementing
increased farm biosecurity and controls on animal trade (of
ESBL/AmpC-carriers), or by improving hygiene throughout the
food chain (implementing general postharvest controls for food-
borne pathogens). Because most evidence is available for high
prevalence of ESBL/AmpC-producing bacteria in the poultry
production pyramid [16, 36, 48, 49], and their consequent in-
volvement in public health [34, 50], it is of high priority to
reduce selection pressure imposed by the use of antimicrobials,
to prevent vertical transmission from the top of the poultry pro-
duction pyramid and to prevent local recirculation within ﬂocks.
CONCLUSIONS
Because of the ubiquity of ESBL- and AmpC-producing bacteri-
al strains and of the associated genetic determinants, it is unlike-
ly that any single control measure will be sufﬁcient to limit their
transmission through the food chain. Nevertheless, it is of para-
mount public health importance that the potential contribution
of food-producing animals or foods to public health is mini-
mized. There is little doubt that the use of cephalosporins and
related compounds has been one of the driving forces in the
spread of organisms exhibiting resistance to such antimicrobials.
Stringent controls are therefore necessary to limit the use of
cephalosporins in food animals. Owing to coresistance, the
general use of antimicrobials is also a risk factor for emergence
and spread of clones and/or plasmids carrying these resistance
genes. As the most problematic area is the high prevalence of
ESBL/AmpC-producing bacteria in the poultry production
pyramid and their consequent involvement of such organisms
in public health, in the ﬁrst instance controls should be targeted
at poultry production. As an example, a strong correlation
between a reduction in ceftiofur-resistant Salmonella and E. coli
from human infections and retail poultry and withdrawal of cef-
tiofur for prophylaxis in hatcheries has been reported in
Canada. Of importance are also measures to control dissemina-
tion, for example, by implementing increased farm biosecurity
and controls on animal trade (of ESBL/AmpC carriers), by im-
proving hygiene throughout the food chain, and by implement-
ing other general postharvest controls for foodborne pathogens.
The effectiveness of any control measures should be monitored
on a regular basis by targeted surveys of food animals and foods
for cephalosporin-resistant bacteria, using selective isolation
methods and preenrichment of samples as necessary.
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